Carmen Kahatt

3.2k total citations · 2 hit papers
97 papers, 2.0k citations indexed

About

Carmen Kahatt is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Carmen Kahatt has authored 97 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Oncology, 41 papers in Pulmonary and Respiratory Medicine and 38 papers in Molecular Biology. Recurrent topics in Carmen Kahatt's work include Lung Cancer Research Studies (38 papers), Cancer Treatment and Pharmacology (28 papers) and Cancer therapeutics and mechanisms (25 papers). Carmen Kahatt is often cited by papers focused on Lung Cancer Research Studies (38 papers), Cancer Treatment and Pharmacology (28 papers) and Cancer therapeutics and mechanisms (25 papers). Carmen Kahatt collaborates with scholars based in Spain, France and United States. Carmen Kahatt's co-authors include François Lokiec, Keyvan Rezaï, Patrice Herait, Esteban Cvitkovic, Martín Cullell-Young, Emmanuel Raffoux, Bruno Quesnel, Anastasios Stathis, A. Taamma and Étienne Brain and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Carmen Kahatt

92 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

2016 336 citations Keyvan Rezaï, Carmen Kahatt et al. profile →
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

2016 328 citations Keyvan Rezaï, Carmen Kahatt et al. profile →

Peers

Countries citing papers authored by Carmen Kahatt

Since Specialization

Citations

This map shows the geographic impact of Carmen Kahatt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carmen Kahatt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carmen Kahatt more than expected).

Fields of papers citing papers by Carmen Kahatt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carmen Kahatt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carmen Kahatt. The network helps show where Carmen Kahatt may publish in the future.

Co-authorship network of co-authors of Carmen Kahatt

This figure shows the co-authorship network connecting the top 25 collaborators of Carmen Kahatt. A scholar is included among the top collaborators of Carmen Kahatt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carmen Kahatt. Carmen Kahatt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma 2025 ·Future Oncology ·Gregory M. Coté, Sant P. Chawla, George D. Demetri, Bernd Kasper, Robin L. Jones, Javier Martín‐Broto, (unknown), (unknown), Salvatore Tafuto, Giuseppe Badalamenti, (unknown), (unknown), Jean‐Yves Blay, (unknown), Cristian Fernández, Antonio Nieto, Carmen Kahatt, Vicente Alfaro, Axel Le Cesne	0
2	Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumors 2025 ·Investigational New Drugs ·Alejandro Falcón, Santiago Ponce, Gregory M. Coté, (unknown), W. Marston Linehan, Bruno Bockorny, (unknown), Carmen Kahatt, Sara Martínez, Pablo Zubiaur, Mariano Siguero, Martín Cullell-Young, (unknown), Jon Zugazagoitia, Luis Paz‐Ares	0
3	Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug–Drug Interaction Study 2024 ·Marine Drugs ·Irene Moreno, (unknown), Emiliano Calvo, Salvador Fudio, Carmen Kahatt, (unknown), (unknown), (unknown), (unknown), (unknown), Ali Zeaiter, Rubin Lubomirov	3
4	Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study 2024 ·Pharmaceuticals ·Irene Moreno, (unknown), Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Cristian Fernández-Palomo, (unknown), (unknown), (unknown), (unknown), Ali Zeaiter, Rubin Lubomirov	1
5	1790P Phase II data of lurbinectedin (LUR) and irinotecan (IRI) in relapsed small cell lung cancer (SCLC) patients (pts) with chemotherapy-free interval (CTFI)>30 days (d) 2024 ·Annals of Oncology ·Jon Zugazagoitia, (unknown), (unknown), Amparo Sánchez-Gastaldo, (unknown), Gregory M. Coté, (unknown), (unknown), (unknown), (unknown), (unknown), Santiago Ponce Aix, (unknown), (unknown), Sagrario Martínez Cortijo, José Antonio López-Vilariño, Carmen Kahatt, Javier Gómez, Luis Paz‐Ares	2
6	EP13.07-06 Efficacy of Platinum Given after Lurbinectedin in Sensitive Relapsed SCLC Patients 2023 ·Journal of Thoracic Oncology ·José Trigo, (unknown), Khalil Zaman, María Ángeles Sala, (unknown), (unknown), José Antonio López-Vilariño, Christian Fernandez, Antonio Nieto, Carmen Kahatt, Ali Zeaiter, A. Antón, Javier Valdivia, (unknown), (unknown)	0
7	Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study 2022 ·Clinical Cancer Research ·Vivek Subbiah, Irene Braña, Alessandra Longhi, Valentina Boni, Jean‐Pierre Delord, Ahmad Awada, Pascaline Boudou‐Rouquette, John Sarantopoulos, Geoffrey I. Shapiro, Anthony Elias, Ravin Ratan, Cristian Fernández, Carmen Kahatt, Martín Cullell-Young, Mariano Siguero, Ali Zeaiter, Sant P. Chawla	18
8	Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer 2022 ·ESMO Open ·Ahmad Awada, Valentina Boni, Víctor Moreno, (unknown), Carmen Kahatt, (unknown), Mariano Siguero, Carlos Fernández‐Teruel, Martín Cullell-Young, Josep Tabernero	2
9	Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study 2021 ·Investigational New Drugs ·M.E. Olmedo, Martin Förster, Víctor Moreno, (unknown), Irene Braña, Michael Flynn, Bernard Doger, Maria J. de Miguel, José Antonio López-Vilariño, Rafael N. Nuñez, Carmen Kahatt, Martín Cullell-Young, Ali Zeaiter, Emiliano Calvo	14
10	551P Phase I study of lurbinectedin in Japanese patients with pretreated advanced tumours: Final results 2020 ·Annals of Oncology ·Shunji Takahashi, Toshio Shimizu, Toshihiko Doi, José Antonio López-Vilariño, Robert N. Martin, Carmen Kahatt, (unknown), Hiromi Sasamoto, Ali Zeaiter	2
11	P2.12-13 Lurbinectedin (L) Combined with Paclitaxel (P) or Irinotecan (I) in Relapsed SCLC. Results from Two Phase Lb Trials 2019 ·Journal of Thoracic Oncology ·Santiago Ponce, Emiliano Calvo, Maria J. de Miguel, C. Sessa, M.J. Flor, A. Drilon, Alejandro Falcón, Ioan Şimon, Ramiro Manzano-Núñez, (unknown), (unknown), José Antonio López-Vilariño, Salvador Fudio, Mariano Siguero, Martín Cullell-Young, Carmen Kahatt, Ali Zeaiter, Luis Paz‐Ares	3
12	P1.12-20 Overall Survival with Lurbinectedin Plus Doxorubicin in Relapsed SCLC. Results from an Expansion Cohort of a Phase Ib Trial 2018 ·Journal of Thoracic Oncology ·Martin Förster, Víctor Moreno, Emiliano Calvo, M.E. Olmedo, (unknown), José Antonio López-Vilariño, Ramiro Manzano-Núñez, Carmen Kahatt, Arturo Soto-Matos	7
13	P3.06-002 ATLANTIS Trial: Phase III Study of PM01183/Doxorubicin vs. CAV or Topotecan in SCLC after One Platinum-Containing Line 2017 ·Journal of Thoracic Oncology ·Anna F. Farago, Martin Förster, Luis Paz‐Ares, (unknown), Sergio Szyldergemajn, José Antonio López-Vilariño, (unknown), Carmen Kahatt, Arturo Soto-Matos, M.E. Olmedo	1
14	Activity of lurbinectedin as single agent and in combination in patients with advanced small cell lung cancer (SCLC) 2017 ·Annals of Oncology ·(unknown), Martin Förster, Emiliano Calvo, Víctor Moreno, (unknown), (unknown), Carmen Kahatt, Pilar Lardelli, (unknown), Arturo Soto-Matos	5
15	Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study 2017 ·Annals of Oncology ·Emiliano Calvo, Víctor Moreno, Michael Flynn, Esther Holgado, M.E. Olmedo, (unknown), Carmen Kahatt, José Antonio López-Vilariño, Mariano Siguero, Carlos Fernández‐Teruel, Martín Cullell-Young, (unknown), Martin Förster	65
16	Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study 2014 ·Annals of Oncology ·Suzette Delaloge, (unknown), Tomasz Byrski, Joanne L. Blum, Anthony Gonçalvès, Mario Campone, Pilar Lardelli, Carmen Kahatt, Antonio Nieto, Martín Cullell-Young, Jan Lubiński	31
17	A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin 2012 ·Cancer Chemotherapy and Pharmacology ·Federica Grosso, Maurizio D’Incalci, (unknown), Antonio Nieto, Carlos Fernández‐Teruel, Vicente Alfaro, Pilar Lardelli, (unknown), Javier Gómez, Carmen Kahatt, Arturo Soto-Matos, Ian Judson	22
18	Pharmacokinetics, Metabolism, and Routes of Excretion of Intravenous Irofulven in Patients with Advanced Solid Tumors 2006 ·Drug Metabolism and Disposition ·Angélo Paci, Keyvan Rezaï, Alain Deroussent, Dominique de Valeriola, Micheline Ré, (unknown), Esteban Cvitkovic, Carmen Kahatt, Ajit Shah, Stephen J. Waters, (unknown), Gilles Vassal, François Lokiec	9
19	A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors 2006 ·Investigational New Drugs ·Werner Hilgers, Sandrine Faivre, (unknown), Jérôme Alexandre, François Lokiec, François Goldwasser, Éric Raymond, Carmen Kahatt, A. Taamma, (unknown), John R. MacDonald, Jean-Louis Misset, Esteban Cvitkovic	13
20	Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients 2004 ·Journal of Clinical Oncology ·Alejandro Yovine, M. Riofrio, Jean‐Yves Blay, Étienne Brain, Jérôme Alexandre, Carmen Kahatt, A. Taamma, José Jimeno, C. Martin, Yacine Salhi, Esteban Cvitkovic, J. L. Misset	261

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact